Akebia Therapeutics Inc. (NASDAQ:AKBA) traded with a subtraction of $0.0 to $1.29 on Thursday, a downside of -0.24 percent. An average of 709,758 shares of common stock have been traded in the last five days. There was a gain of $0.0500 in the past week, and it reached a new high 20 times over the past 12 months. The last 20 days have seen an average of 1,708,989 shares traded, while the 50-day average volume stands at 1,865,760.
AKBA stock has decreased by -11.25% in the last month. The company shares reached their 1-month lowest point of $1.1900 on 08/21/23. With the stock rallying to its 52-week high on 08/01/23, shares of the company touched a low of $0.24 and a high of $1.84 in 52 weeks. It has reached a new high 14 times so far this year and achieved 123.03% or $0.7230 in price. In spite of this, the price is down -30.06% from the 52-week high.
Insider Transactions
AKBA stock investors should be aware that Akebia Therapeutics Inc. (AKBA) stock had its last reported insider trading activity 91 days ago on May 25. In this transaction, the insider spent $116,760. SVP, Chief Legal Officer, Hadas Nicole R., disposed of 63,186 shares at a price of $1.22 on May 25. The insider now owns more than $77,270 worth of shares. Prior to that, SVP, Chief Medical Officer Burke Steven Keith went on to Sale 63,567 shares at $1.07 each on May 16. An amount of $67,890 was transacted.
Valuation Metrics
Akebia Therapeutics Inc. (AKBAstock’s beta is 0.85. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.88.
Financial Health
The quick ratio of Akebia Therapeutics Inc. for the three months ended March 30 was 1.20, and the current ratio was 1.50, indicating that the company is able to meet its debt obligations. Akebia Therapeutics Inc.’s EBITDA margin for the year ending March 30 is -9.54%, while its operating margin for the same period stands at -17.10%. Its gross profit as reported stood at $207.81 million compared to revenue of $292.6 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Akebia Therapeutics Inc.’s return on assets was -14.20%.
Earnings Surprise
For the three-month period that ended March 30, Akebia Therapeutics Inc. had $26.3 million in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$26.22 million in the quarter, while revenues of -$7.55 million were shrunk -138.06%. The analyst consensus anticipated Akebia Therapeutics Inc.’s latest quarter earnings to come in at -$0.15 per share, but it turned out to be -$0.14, a 6.70% surprise. For the quarter, EBITDA amounted to -$15.53 million. Shareholders own equity worth $185.93 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Akebia Therapeutics Inc. (AKBA) price momentum. RSI 9-day as of the close on 23 August was 45.55%, suggesting the stock is Neutral, with historical volatility in this time frame at 37.85%.
As of today, AKBA’s price is $1.2660 +4.00% or $0.0500 from its 5-day moving average. AKBA is currently trading -14.47% lower than its 20-day SMA and +131.98% higher than its 100-day SMA. However, the stock’s current price level is +5.69% above the SMA50 and +379.53% above the SMA200.
The stochastic %K and %D were 19.38% and 14.09%, respectively, and the average true range (ATR) was 0.1115. With the 14-day stochastic at 23.91% and the average true range at 0.1199, the RSI (14) stands at 47.87%. The stock has reached 0.0089 on the 9-day MACD Oscillator while the 14-day reading was at -0.0588.
Analyst Ratings
Piper Sandler upgraded Akebia Therapeutics Inc. (NASDAQ: AKBA) to a an Overweight rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Akebia Therapeutics Inc. (AKBA) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell AKBA, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is AKBA’s price target for the next 12 months?
Analysts predict a range of price targets between $2.00 and $4.00, with a median target of $3.00. Taking a look at these predictions, the average price target given by analysts for Akebia Therapeutics Inc. (AKBA) stock is $3.00.
